The European Alliance of Associations for Rheumatology, in partnership with the Pediatric Rheumatology European Society (PReS ...

sJIA and AOSD share the same features, and the same four major symptoms. However, the two conditions have traditionally been separated by a person's age at diagnosis. Until now, before the age of ...

People with AOSD, whilst experiencing the same disease, have been left behind. To address this, EULAR has worked with PReS to ...

The European Alliance of Associations for Rheumatology – in partnership with the Paediatric Rheumatology European Society (PReS) has developed new recommendations for the diagnosis and management of ...

The UK's cost-effectiveness agency NICE has recommended that Sobi's Kineret can be used to treat NHS patients with Still's disease, a rare form of arthritis affecting children and adults.

Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's ...

The purpose of these two prospective studies is to assess the efficacy and safety of emapalumab in controlling MAS in patients with Still's disease, including sJIA and AOSD, who had an inadequate ...